BioWorld

Oct. 24, 2005

Syntonix, Boehringer Enter $63M Inhaled Peptide Deal

For the second time this year, an international drug company is showing a strong interest in Syntonix Pharmaceuticals Inc.'s Synfusion and Transceptor technologies - this time to the tune of up to $63 million. (BioWorld Today) Read More

Maxygen Awarded $14.4M Of Fed's Money For HIV Vaccine

Blocking Immune Signals To Brain Helps Sickness Healing

Biodefense Budget Dissected; Some Feel More Money Needed

Other News To Note

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for Jan 30, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...